Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza^*

References

• Smith NM, Bresee JS, Shay DK, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55:1–42
   PubMedGoogle Scholar
• Committee on Infectious Diseases, American Academy of Pediatrics. Reduction of the influenza burden in children. Pediatrics 2002;110:1246–52
   PubMedGoogle Scholar
• Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003–2004. New Engl J Med 2005;353:2559–66
   PubMed Web of Science ®Google Scholar
• Meibalane R, Sedmak GV, Sasidharan P, et al. Outbreak of influenza in a neonatal intensive care unit. J Pediatr 1977;91:974–6
   PubMed Web of Science ®Google Scholar
• Chiu SS, Tse CY, Lau YL, Peiris M. Influenza A infection is an important cause of febrile seizures. Pediatrics 2001;108: E63
   PubMed Web of Science ®Google Scholar
• Thomson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. J Am Med Assoc 2004;292:1333–40
   Web of Science ®Google Scholar
• Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine 2000;18:957–1030
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial [US Oral Neuraminidase Study Group]. J Am Med Assoc 2000;283:1016–24
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial [Neuraminidase Inhibitor Flu Treatment Investigator Group]. Lancet 2000;355:1845–50
   PubMed Web of Science ®Google Scholar
• Martin C, Mahoney P, Ward P. Oral oseltamivir reduces febrile illness in patients considered at high risk of influenza complications [Abstract W22–7]. In: Options for the control of influenza IV. New York (NY): Excerpta Med; 2001. p. 807–11
   Google Scholar
• Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. Br Med J 2003;326:1235–40
   PubMed Web of Science ®Google Scholar
• Anon. Tamiflu. Summary of product characteristics. Nutley (NJ): Roche; 2006
   Google Scholar
• Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127–33
   PubMed Web of Science ®Google Scholar
• Prober CG. Antiviral therapy for influenza virus infection. Semin Pediatr Infect Dis 2002;13:31–9
   PubMedGoogle Scholar
• Schmidt AC. Antiviral therapy for influenza: a clinical and economic comparative review. Drugs 2004;64:2031–46
   PubMed Web of Science ®Google Scholar
• Berndt ER, Bir A, Busch SH, et al. The medical treatment of depression, 1991–1996: productive inefficiency, expected outcome variations, and price indexes. J Health Econ 2002; 21:373–96
   PubMed Web of Science ®Google Scholar
• Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. J Am Med Assoc 2000;284: 1655–63
   PubMed Web of Science ®Google Scholar
• Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychol 2002;63:963–71
   Web of Science ®Google Scholar
• Javitz H, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002;46:850–60
   PubMed Web of Science ®Google Scholar
• Bureau of Labor Statistics. Consumer Price Indexes. Available at: http://www.bls.gov/cpi/home.htm [accessed November 1, 2004]
   Google Scholar
• Centers for disease control and prevention. 2004–05 US influenza season summary. Influenza (Flu) Weekly Report: influenza summary update. Available at: http://www.cdc. gov/flu/weekly/weeklyarchives2004–2005/04–05summary.htm [accessed January 30, 2006]
   Google Scholar
• Estimated influenza vaccination coverage among adults and children – United States, September 1, 2004–January 21, 2005. Morb Mortal Wkly Rep 2005;54:304–7
   PubMedGoogle Scholar
• Kaiser L, Watt C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:1667–72
   PubMed Web of Science ®Google Scholar
• Mays GP, Claxton G, White J. Managed care rebound? Recent changes in health plans’ cost containment strategies. Health Aff (Millwood). 2004; July-December Suppl Web Exclusives (W4):427–36
   Google Scholar
• Kaiser Family Foundation. Statehealthfacts.org: HMO Penetration Rate, 2003. Available at: http://www.statehealthfacts.kff.org/ cgi-bin/healthfacts.cgi [accessed November 1, 2004]
   Google Scholar
• Kaiser Family Foundation. Trends and indicators in the changing health care marketplace, 2004. Publication Number 7031. Available at: www.kff.org/insurance/7031/index.cfm [accessed January 2006]
   Google Scholar
• Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003;51:123–9
   PubMed Web of Science ®Google Scholar